State Street’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-68,247
Closed -$5.54K – 4917
2022
Q4
$5.54K Hold
68,247
– – ﹤0.01% 4829
2022
Q3
$9K Hold
68,247
– – ﹤0.01% 4896
2022
Q2
$19K Hold
68,247
– – ﹤0.01% 4882
2022
Q1
$21K Hold
68,247
– – ﹤0.01% 4880
2021
Q4
$157K Buy
68,247
+57,200
+518% +$169K ﹤0.01% 4445
2021
Q3
$26K Buy
+11,047
New +$41.9K ﹤0.01% 4677
2015
Q1
– Sell
-875
Closed -$6K – 3696
2014
Q4
$6K Sell
875
-90
-9% -$704 ﹤0.01% 3691
2014
Q3
$9K Hold
965
– – ﹤0.01% 3671
2014
Q2
$9K Hold
965
– – ﹤0.01% 3631
2014
Q1
$14K Hold
965
– – ﹤0.01% 3626
2013
Q4
$23K Hold
965
– – ﹤0.01% 3587
2013
Q3
$31K Hold
965
– – ﹤0.01% 3558
2013
Q2
$31K Buy
+965
New +$33.2K ﹤0.01% 3484

Other funds holding STAB

State Street's STAB Position: Q1 2023 in Review

State Street sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 68,247 shares — an estimated $5.54K sold.

State Street first reported a position in STAB in Q2 2013 and held it in 13 quarters. The position peaked at $157K in Q4 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • State Street reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • State Street sold 68,247 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $5.54K.
  • State Street first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 13 quarters.
  • State Street's Statera Biopharma, Inc. Common Stock position peaked at $157K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.